23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS Post navigationPreviousPrevious post:Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodNextNext post:FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancerRelated PostsPublication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019Webcast on masitinib in severe asthma on Monday, December 2, 2019November 26, 2019Summary of webcast with Key Opinion Leaders on Indolent Systemic MastocytosisNovember 25, 2019Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019Positive top-line Phase 3 results for masitinib in severe asthmaNovember 7, 2019AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDANovember 7, 2019
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019
